Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status

• David Baker,
• Milan Bimali,
• Luis Carrillo,
• Archana Sachedina,
• Daisy Alapat,
• Md Shadiqul Hoque,
• Mathew Kottarathara,
• Richa Parikh,
• Amani Erra,
• Angel A. Mitma,
• Pankaj Mathur,
• Yetunde Ogunsesan,
• Lakshmi Yarlagadda,
• Sravani Gundarlapalli,
• Sharmilan Thanendrarajan,
• Maurizio Zangari,
• Frits van Rhee,
• Guido Tricot,
• Carolina Schinke

Affiliations

David Baker

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Milan Bimali

Arkansas Children’s Nutrition Center, Arkansas Children's Hospital, Little Rock, AR; Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock

Luis Carrillo

Department of Pathology, University of Arkansas for Medical Sciences, Little Rock

Archana Sachedina

Department of Radiology, University of Arkansas for Medical Sciences, Little Rock

Daisy Alapat

Department of Pathology, University of Arkansas for Medical Sciences, Little Rock

Md Shadiqul Hoque

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Mathew Kottarathara

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Richa Parikh

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Amani Erra

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Angel A. Mitma

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Pankaj Mathur

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Yetunde Ogunsesan

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Lakshmi Yarlagadda

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Sravani Gundarlapalli

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Sharmilan Thanendrarajan

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Maurizio Zangari

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Frits van Rhee

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Guido Tricot

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock

Carolina Schinke

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock